IJMS | Free Full-Text | Sphingosine-1-Phosphate (S1P) Lyase Inhibition Aggravates Atherosclerosis and Induces Plaque Rupture in ApoE−/− Mice
Ligand chain length drives activation of lipid G protein-coupled receptors | Scientific Reports
Targeting sphingosine-1-phosphate lyase as an anabolic therapy for bone loss | Nature Medicine
IJMS | Free Full-Text | Sphingosine-1-Phosphate (S1P) Lyase Inhibition Aggravates Atherosclerosis and Induces Plaque Rupture in ApoE−/− Mice
LEOPARD S1P, 3Move, Products | Giasco
S1P Receptor Modulators in IBD
IJMS | Free Full-Text | The Effectiveness of Anti-Apoptotic Agents to Preserve Primordial Follicles and Prevent Tissue Damage during Ovarian Tissue Cryopreservation and Xenotransplantation
Regulation of cell survival by sphingosine-1-phosphate receptor S1P1 via reciprocal ERK-dependent suppression of Bim and PI-3-kinase/protein kinase C-mediated upregulation of Mcl-1 | Cell Death & Disease
IJMS | Free Full-Text | The Effectiveness of Anti-Apoptotic Agents to Preserve Primordial Follicles and Prevent Tissue Damage during Ovarian Tissue Cryopreservation and Xenotransplantation
Work Shoes Titan S1P Low Cut ZCTP | Beorol d.o.o
Ligand chain length drives activation of lipid G protein-coupled receptors | Scientific Reports
Ponesimod | 99.92%(HPLC) | In Stock | S1P Receptor modulator
Cador - Sportieve lage ESD-veiligheidsschoen | Safety Jogger
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease | Nature Reviews Gastroenterology & Hepatology
Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial - The Lancet Neurology
Characterization of cholesterol homeostasis in sphingosine-1-phosphate lyase-deficient fibroblasts reveals a Niemann-Pick disease type C-like phenotype with enhanced lysosomal Ca2+ storage | Scientific Reports
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies - The Lancet